EUVIMEDEUVIMED entdecken
Open Access

Clinical characteristics, molecular aberrations, treatments, and outcomes of malignant histiocytosis

Gordon J Ruan iD, Saurabh Zanwar iD, Aishwarya Ravindran iD, Susan Schram, Jithma P Abeykoon, Antonious Hazim iD, Jason R Young, Mithun V Shah iD, N Nora Bennani, Liuyan Jiang, Diana Morlote, Karen L Rech und 3 weitere

American Journal of Hematology · 2024-05 · 99 (5) · 871-879

DOI: 10.1002/ajh.27263 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hematology, online erschienen am 26.02.2024. Verfasst von Gordon J Ruan und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Histiocytic Sarcoma. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, University of Iowa.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Malignant histiocytosis (MH) is an extremely rare neoplasm of the macrophage–dendritic cell lineage. We report the clinical characteristics, molecular aberrations, treatments, and outcomes of patients with MH seen at two referral centers from January 2000 to May 2023. We identified 43 patients with MH, of which 26 had histiocytic sarcoma (MH‐H), 9 interdigitating dendritic cell sarcoma (MH‐IDC), and 8 Langerhans cell sarcoma (MH‐LC). The median age at diagnosis was 61 years (range, 3–83). Thirty‐three patients (77%) had multifocal disease, while 10 had unifocal involvement. Tumor specimens from 22 patients (51%) underwent targeted next generation sequencing, and 19 of 22 (86%) had at least one pathogenic mutation, including mutations in MAPK pathway genes (73%). The median overall survival (OS) among the entire cohort was 16 months (95% CI: 8–50). The outcomes of those with multifocal disease were significantly shorter than their unifocal counterpart: median OS of 10 months versus 50 months ( p = .07). Patients with risk organ involvement (bone marrow, spleen, or liver) had significantly inferior outcomes. Chemotherapy and surgery were the most common first‐line treatments for multifocal and unifocal disease, respectively. While the outcome for patients with multifocal disease was poor, there was a subset of patients who had durable responses to treatment. Our study highlights that MH has heterogeneous clinical presentation, frequent oncogenic mutations, and prognosis, which is strongly tied to disease extent and type of organ involvement.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Histiocytic SarcomaHumansChild, PreschoolChildAdolescentYoung AdultAdultMiddle AgedAgedAged, 80 and overMacrophagesBone MarrowPrognosisLiver

Autor:innen und Institutionen

  • Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
  • Division of Laboratory Medicine-Hematopathology, Department of Pathology, The University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Sawtooth Epidemiology & Infectious Diseases, Boise, Idaho, USA.
  • Department of Radiology, Mayo Clinic, Jacksonville, Florida, USA.
  • Department of Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, Florida, USA.

ORCID-Profile: Gordon J Ruan, Saurabh Zanwar, Aishwarya Ravindran, Antonious Hazim, Mithun V Shah, Gaurav Goyal

Förderung

  • NCI NIH HHS
  • University of Iowa

Zitieren

APA

Ruan, G. J., Zanwar, S., Ravindran, A., Schram, S., Abeykoon, J. P., Hazim, A., Young, J. R., Shah, M. V., Bennani, N. N., Jiang, L., Morlote, D., Rech, K. L., Goyal, G., Go, R. S., & Mayo Clinic‐University of Alabama at Birmingham Histiocytosis Working Group (2024). Clinical characteristics, molecular aberrations, treatments, and outcomes of malignant histiocytosis. American Journal of Hematology, 99(5), 871-879. https://doi.org/10.1002/ajh.27263

Vancouver

Ruan GJ, Zanwar S, Ravindran A, Schram S, Abeykoon JP, Hazim A, et al. Clinical characteristics, molecular aberrations, treatments, and outcomes of malignant histiocytosis. American Journal of Hematology. 2024;99(5):871-879. doi:10.1002/ajh.27263

BibTeX
@article{Ruan2024,
  author = {Ruan, Gordon J and Zanwar, Saurabh and Ravindran, Aishwarya and Schram, Susan and Abeykoon, Jithma P and Hazim, Antonious and Young, Jason R and Shah, Mithun V and Bennani, N Nora and Jiang, Liuyan and Morlote, Diana and Rech, Karen L and Goyal, Gaurav and Go, Ronald S and Mayo Clinic‐University of Alabama at Birmingham Histiocytosis Working Group, Mayo Clinic‐University of Alabama at Birmingham Histiocytosis Working Group},
  title = {Clinical characteristics, molecular aberrations, treatments, and outcomes of malignant histiocytosis},
  journal = {American Journal of Hematology},
  year = {2024},
  volume = {99},
  number = {5},
  pages = {871--879},
  doi = {10.1002/ajh.27263}
}
Kostenlos starten →